Welcome to our dedicated page for Peraso SEC filings (Ticker: PRSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Peraso Inc. (NASDAQ: PRSO) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures, drawn from the U.S. Securities and Exchange Commission’s EDGAR system. Peraso is a fabless semiconductor company focused on 60 GHz unlicensed and 5G mmWave wireless technology, and its filings offer detailed insight into its capital structure, governance, financing activities and financial performance.
Investors can review Form 10‑K annual reports and Form 10‑Q quarterly reports to understand how Peraso describes its business, risk factors and results of operations, including its focus on mmWave chipsets, antenna modules, software and IP. These core filings typically include segment information, discussion of fixed wireless access and other applications, and management’s analysis of revenue, expenses and non-GAAP metrics.
Peraso’s frequent Form 8‑K current reports document material events such as earnings releases, strategic review updates, prospectus supplements for at-the-market equity offerings, changes in outstanding securities, and governance matters. For example, 8‑K filings describe the company’s ongoing strategic review and interactions with Mobix Labs, amendments to its Amended and Restated 2019 Stock Incentive Plan, the appointment of director Cees Links, and notices related to regaining compliance with Nasdaq’s minimum bid price requirement.
This page also surfaces registration statements and prospectus supplements that outline Peraso’s at-the-market offering program, as well as disclosures on outstanding warrants, stock options, restricted stock units and the Series A special voting preferred stock. Where available, Form 4 insider transaction reports can be used to track equity transactions by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify items such as changes in capital structure, non-GAAP reconciliations, board and committee changes, and updates on strategic alternatives. Real-time updates ensure that new Peraso filings appear promptly, giving investors an efficient way to follow the company’s regulatory history and ongoing reporting.
PRSO is updating its shelf registration to allow additional at-the-market sales of common stock through Ladenburg Thalmann. The company may now offer and sell, from time to time, shares of common stock having an aggregate offering price of up to $3,150,000 under its existing Sales Agreement, in addition to approximately $4,095,176 of shares already sold under prior supplements.
These sales are made under Form S-3 General Instruction I.B.6, which limits primary offerings to no more than one-third of public float in any 12-month period while public float remains below $75,000,000. As of November 21, 2025, PRSO’s public float was about $21,229,538, based on 9,150,663 shares held by non-affiliates. The stock trades on Nasdaq Capital Market under the symbol PRSO, with a last reported price of $0.8839 per share on November 20, 2025.
Peraso Inc. reported Q3 results with total net revenue of $3.234 million, down 20% year over year, as the business shifts from legacy memory ICs to mmWave products. Product revenue was $3.062 million, led by mmWave ICs of $2.276 million, while memory ICs contributed $0.072 million following the product line’s end‑of‑life. Gross profit was $1.817 million.
Net loss for the quarter was $1.210 million (basic and diluted loss per share of $0.17), compared with a $2.712 million net loss a year ago. Cash and cash equivalents were $1.865 million at quarter end, and operating cash outflow was $4.555 million for the first nine months. The company raised liquidity through an ATM program (net $2.270 million year‑to‑date) and warrant inducement offerings (net $0.933 million earlier and approximately $0.9 million in September). Management states substantial doubt about the company’s ability to continue as a going concern absent additional capital. Peraso is conducting a strategic review and, on October 30, 2025, entered a mutual confidentiality agreement with Mobix Labs regarding its unsolicited proposals. Peraso also regained compliance with Nasdaq’s $1.00 minimum bid price on September 19, 2025.
Peraso Inc. (PRSO) furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025, attached as Exhibit 99.1. The release includes GAAP results alongside non-GAAP measures used by management to evaluate performance.
The non-GAAP metrics exclude stock-based compensation, amortization of intangibles from the 2021 Peraso Technologies acquisition, severance costs, and changes in fair value of warrant liabilities. Adjusted EBITDA is defined as GAAP net income (loss) excluding these items plus interest, depreciation and income taxes. The company notes severance amounts were fully paid during the quarter ended September 30, 2025.
The information in the report and Exhibit 99.1 is being furnished, not filed, and includes reconciliations to the most comparable GAAP measures in the press release.
Mobix Labs filed a Schedule TO‑C as a pre‑commencement communication regarding a potential tender offer for Peraso, Inc. common stock. No tender offer has been commenced. If launched, Mobix Labs will file a Schedule TO with an offer to purchase, letter of transmittal, and related documents, and Peraso would file a Schedule 14D‑9.
Investors will be able to access any related documents, if and when available, free of charge at the SEC’s website and Mobix Labs’ investor relations site.
Peraso Inc. (PRSO) announced a confidentiality agreement with Mobix Labs on October 30, 2025, as part of its ongoing review of strategic alternatives. The pact includes customary terms, notably a mutual 12-month standstill and non-solicitation provisions.
This is an administrative step that allows both companies to exchange information under agreed boundaries while Peraso evaluates potential paths. No financial terms or transactions were disclosed in connection with this notice.
Peraso Inc. disclosed that it filed a new prospectus supplement to increase the capacity of its at-the-market equity program with Ladenburg Thalmann. The supplement raises the maximum amount of common stock that can be issued under the existing Sales Agreement to up to an aggregate of $1,750,000 of shares.
This new limit is separate from the $2,686,953 in shares that have already been sold under the agreement. The shares are being offered under Peraso’s effective Form S-3 shelf registration statement and related base prospectus, as further detailed in prior and current prospectus supplements.
PRSO is updating its at-the-market stock offering program, allowing it to sell additional common shares with an aggregate offering price of up to $1,750,000 through Ladenburg Thalmann under an existing sales agreement. This fits within Form S-3 rules that cap primary offerings at one-third of its public float.
The company also outlines an ongoing unsolicited approach from Mobix Labs, which has moved from an initial stock-based proposal to a revised all-cash indication of $1.30 per share. Mobix has discussed a potential hostile exchange offer but, as of October 9, 2025, has not commenced any tender or exchange offer. The board is conducting a strategic review with financial and legal advisors and states there is no assurance any transaction with Mobix or others will occur.
Peraso Inc. filed an S-3 shelf registration to register shares for resale by certain selling stockholders and to register shares issuable upon exercise of outstanding warrants and options. The filing shows up to 1,019,047 shares issuable on exercise of the Warrants, and assumes October 7, 2025 as a full-exercise date producing 8,809,757 total shares and Exchangeable Shares outstanding after exercise. Several broker-dealer placement agent warrants and inducement warrants are listed (including placement agent warrants issued to Ladenburg Thalmann and affiliates). The capitalization disclosures list multiple warrant series and option pools, including 3,974,520 shares issuable upon exercise of Series A warrants at $2.25, 1,293,650 Series C warrants at $1.61, and other series with specified exercise prices. The prospectus also lists selling stockholders with specific pre- and post-offering beneficial ownership percentages and a range of permitted distribution methods. Filing exhibits and fees are enumerated and officers signed the registration.
Mobix Labs, Inc. has filed a Schedule TO-C describing pre-commencement communications for a potential tender offer to acquire the issued and outstanding shares of Peraso, Inc. common stock. This filing makes clear that no tender offer has begun yet and that any future offer would be detailed in formal tender offer materials filed on Schedule TO, along with Peraso’s response on Schedule 14D-9.
The communication emphasizes that Peraso security holders should carefully review any future tender offer documents and recommendation statement before deciding whether to tender their shares. It also includes extensive forward-looking statement disclosures, outlining uncertainties such as Peraso’s willingness to engage, regulatory approvals, financing conditions, market volatility, and integration risks if a transaction is ultimately pursued.
Peraso Inc. disclosed the detailed schedule of outstanding equity instruments that could convert into common stock, listing option, warrant, restricted stock unit, and reserve quantities. Key items include 837,380 shares held in abeyance, 1,333,794 shares from outstanding stock options (weighted average exercise price $3.38), a 213,438 share reserve under its 2019 Stock Incentive Plan, and multiple tranches of warrants across 2022–2025 with exercise prices ranging from $1.25 to $40.00. The filing shows 952,380 Series E warrants dated September 12, 2025 at an exercise price of $1.25 and 66,667 placement agent warrants at $1.475. Aggregating the listed items yields approximately 11.5 million shares of common stock potentially issuable upon exercise or conversion of the instruments disclosed.